Misonidazole neuropathy. A prospective study.
The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group. Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy. Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high 'peak plasma concentration/g misonidazole in each fraction' and especially a high 'area under plasma concentration curve/g misonidazole in each fraction'.
Melgaard
B
B
Neurology Service, Finseninstituttet, Copenhagen, Denmark.
Køhler
O
O
Sand Hansen
H
H
Overgaard
J
J
Munck-Hansen
J
J
Paulson
O B
OB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000139:chemically induced*; D010610:Pharyngeal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy*
D008920:Misonidazole